Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

BACKGROUND: Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene–related peptide (CGRP) receptor antagonist ubrogepant in combination with onabotulinumtoxinA...

Descripción completa

Detalles Bibliográficos
Autores principales: Manack Adams, Aubrey, Hutchinson, Susan, Engstrom, Ella, Ayasse, Nicolai D., Serrano, Daniel, Davis, Linda, Sommer, Katherine, Contreras-De Lama, Janette, Lipton, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399003/
https://www.ncbi.nlm.nih.gov/pubmed/37537578
http://dx.doi.org/10.1186/s10194-023-01622-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399003/
https://www.ncbi.nlm.nih.gov/pubmed/37537578
http://dx.doi.org/10.1186/s10194-023-01622-0

Ejemplares similares